Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Jacobson

Showing results (461-470 of 480) with videos related to

Pageof 48
Sort By:
Journal of Medicinal Chemistry|April 14, 2006
2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonistsMichael D Serby, Hongyu Zhao, Bruce G Szczepankiewicz, et al.
Synthetic and Systems Biotechnology|April 7, 2022
Comparative functional genomics identifies an iron-limited bottleneck in a <i>Saccharomyces cerevisiae</i> strain with a cytosolic-localized isobutanol pathwayFrancesca V Gambacorta, Ellen R Wagner, Tyler B Jacobson, et al.
The American Journal of Tropical Medicine and Hygiene|September 17, 2024
Gestational SARS-CoV-2 Infection in a Ugandan Birth Cohort: High Incidence, Mild Maternal Disease, and Evidence of Association with Transient Infant StuntingKaren B Jacobson, Katharina Röltgen, Brandon Lam, et al.
Cell Reports. Medicine|May 19, 2022
TNF-α<sup>+</sup> CD4<sup>+</sup> T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodiesKattria van der Ploeg, Adam S Kirosingh, Diego A M Mori, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetesPeer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Pediatrics|May 5, 2025
Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023-2024Stephanie A Irving, Bradley Crane, Eric S Weintraub, et al.
Elife|October 14, 2022
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics studyZicheng Hu, Kattria van der Ploeg, Saborni Chakraborty, et al.
Journal of Medicinal Chemistry|July 21, 2006
Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonistsZhili Xin, Michael D Serby, Hongyu Zhao, et al.
Pediatrics|November 12, 2025
Effectiveness of 2023-2024 COVID-19 Vaccines in Children in the United StatesStephanie A Irving, Elizabeth A K Rowley, Sean Chickery, et al.
Journal of Medicinal Chemistry|January 5, 2007
Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitorsJeffrey J Rohde, Marina A Pliushchev, Bryan K Sorensen, et al.
Pageof 48

Showing results (461-470 of 480) with videos related to

Sort By:
Pageof 48
Journal of Medicinal Chemistry|April 14, 2006
2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonistsMichael D Serby, Hongyu Zhao, Bruce G Szczepankiewicz, et al.
Synthetic and Systems Biotechnology|April 7, 2022
Comparative functional genomics identifies an iron-limited bottleneck in a <i>Saccharomyces cerevisiae</i> strain with a cytosolic-localized isobutanol pathwayFrancesca V Gambacorta, Ellen R Wagner, Tyler B Jacobson, et al.
The American Journal of Tropical Medicine and Hygiene|September 17, 2024
Gestational SARS-CoV-2 Infection in a Ugandan Birth Cohort: High Incidence, Mild Maternal Disease, and Evidence of Association with Transient Infant StuntingKaren B Jacobson, Katharina Röltgen, Brandon Lam, et al.
Cell Reports. Medicine|May 19, 2022
TNF-α<sup>+</sup> CD4<sup>+</sup> T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodiesKattria van der Ploeg, Adam S Kirosingh, Diego A M Mori, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetesPeer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Pediatrics|May 5, 2025
Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023-2024Stephanie A Irving, Bradley Crane, Eric S Weintraub, et al.
Elife|October 14, 2022
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics studyZicheng Hu, Kattria van der Ploeg, Saborni Chakraborty, et al.
Journal of Medicinal Chemistry|July 21, 2006
Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonistsZhili Xin, Michael D Serby, Hongyu Zhao, et al.
Pediatrics|November 12, 2025
Effectiveness of 2023-2024 COVID-19 Vaccines in Children in the United StatesStephanie A Irving, Elizabeth A K Rowley, Sean Chickery, et al.
Journal of Medicinal Chemistry|January 5, 2007
Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitorsJeffrey J Rohde, Marina A Pliushchev, Bryan K Sorensen, et al.
Pageof 48